# Tesamorelin + ipamorelin blend

Source: https://aminodesk.com/library/tesamorelin-ipamorelin
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

This blend puts tesamorelin and ipamorelin in one vial. It is sold for fat loss and growth hormone support. No trial has tested the combination in people, and one of the two ingredients cannot be legally compounded.

- **Legal lane:** not FDA-approved as a blend. Ipamorelin is not eligible for pharmacy compounding.
- **Evidence grade:** D for the combination
- **What is in it:** tesamorelin and ipamorelin
- **Established human dose:** none

## What it is

A premixed vial sold by peptide suppliers and some clinics. The ingredients:

- **[tesamorelin](https://aminodesk.com/library/tesamorelin):** FDA-approved as Egrifta, only to reduce excess abdominal fat in people with HIV and lipodystrophy.
- **[ipamorelin](https://aminodesk.com/library/ipamorelin):** not approved; an FDA advisory committee voted 0 to 12 against allowing it to be compounded.

Tesamorelin on its own has real trial evidence, in a specific group: it reduced deep abdominal fat in people with HIV, the fat returned when treatment stopped, and it can worsen blood sugar. None of that was tested in combination with ipamorelin.

## What the evidence shows

There is no trial of this blend. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown.

The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe.

## Legal status

- **Tesamorelin:** a prescription drug approved for one use. Prescribing it for general fat loss is off-label.
- **Ipamorelin:** not approved, and an FDA advisory committee voted 0 to 12, with one abstention, against allowing it to be compounded.
- A vial combining the two has no approved product and no compounding route behind it.

## Reported dosing

**No dose has been established for this blend.**

No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown.

## Safety

- If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it.
- The ratio is fixed by the seller. You cannot adjust one ingredient without moving the others.
- No safety or absorption work exists on the mixture.
- Tesamorelin can worsen blood sugar. Adding a second growth hormone releaser has not been studied.
- A product made outside the pharmacy system has no verified contents or sterility.

## Common questions

### What is in this blend?

tesamorelin and ipamorelin, mixed in one vial.

### Has this blend been tested in people?

No. There is no human trial of the combination.

### Is this blend legal?

No approved product combines them, and ipamorelin is not eligible for compounding.

## Sources

- [Beck et al. 2014: randomized trial of ipamorelin for postoperative ileus (PubMed)](https://pubmed.ncbi.nlm.nih.gov/25331030/)
- [FDA briefing document: ipamorelin-related bulk drug substances (October 2024)](https://www.fda.gov/media/182088/download)
- [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)

The repair blends are compared on [blends and stacks](https://aminodesk.com/stacks).

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
